

**Supplemental Materials For “Systematic review and meta-analysis to estimate the burden of non-fatal and fatal overdose among people who inject drugs living in the U.S. and comparator countries: 2010 – 2023.”**

## Table of Contents

<b>Supplemental Materials For “Systematic review and meta-analysis to estimate the burden of non-fatal and fatal overdose among people who inject drugs living in the U.S. and comparator countries: 2010 – 2023.” .....</b>	1
Appendix 1: PRISMA Checklist .....	3
Appendix 2: Search Strategy.....	5
Appendix 3: Risk of Bias Assessment Scores for Studies Included in the Meta-Analysis (N=58) .....	6
Appendix 4. Results Tables.....	8
<b>Appendix 4.1: Non-Fatal Overdose Sensitivity Analyses (2010 – 2023) .....</b>	8
<b>Appendix 4.2: Non-Fatal and Fatal Overdose Rates Estimates Among PWID (N=58) .....</b>	9
<b>Appendix 4.3: Non-Analyzed Studies with Overlapping Data Summary Table (N=85) .....</b>	11
Appendix 5. Overall Analyses Forest Plots.....	14
<b>Appendix 5.1: Random-Effects Meta-Analysis of North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY.....</b>	14
<b>Appendix 5.2: Random-Effects Meta-Analysis of North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY .....</b>	15
<b>Appendix 5.3: Random-Effects Meta-Analysis of North American Non-Fatal Overdose Rates Per 100 PY .....</b>	16
<b>Appendix 5.4: Random-Effects Meta-Analysis of North American Fatal Overdose Rates Per 100 PY.....</b>	17
Appendix 6. Post 2016 Analyses Forest Plots .....	18
<b>Appendix 6.1: Random-Effects Meta-Analysis of Post-2016 North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY .....</b>	18
<b>Appendix 6.2: Random-Effects Meta-Analysis of Post-2016 North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY .....</b>	19
<b>Appendix 6.3: Random-Effects Meta-Analysis of Post-2016 North American Non-Fatal Overdose Rates Per 100 PY.....</b>	20
<b>Appendix 6.4: Random-Effects Meta-Analysis of Post-2016 North American Fatal Overdose Rates Per 100 PY .....</b>	21
<b>Appendix 6.5: Random-Effects Meta-Analysis of Post-2016 Country-Level Non-Fatal Overdose Rates Per 100 PY .....</b>	22
<b>Appendix 6.6: Random-Effects Meta-Analysis of Post-2016 Country-Level Fatal Overdose Rates Per 100 PY .....</b>	23
Appendix 7. Line Plots .....	24
<b>Appendix 7.1: Line Plot of North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY.....</b>	24
<b>Appendix 7.2: Line Plot of North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY .....</b>	25

## Appendix 1: PRISMA Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Pg. 1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg. 2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg. 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg. 4
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pg. 5; Fig. 1
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pg. 5; App. 2
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	App. 2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 5-6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg. 6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Pg. 6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Pg. 6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 6-7; Fig. 2; App. 3
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Pg. 6-7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Pg. 6-7
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Pg. 6-7
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Pg. 6-7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Pg. 6-7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Pg. 6-7
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Pg. 6-7
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Pg. 6-7
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/a

Section and Topic	Item #	Checklist item	Location where item is reported
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Pg. 8
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	N/a
Study characteristics	17	Cite each included study and present its characteristics.	App. 4.2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	App.3
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Fig. 3-4; App. 4.2; 6.1-6.2
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Fig. 2; App. 3
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pg. 8-10; Tbl. 1; App. 4.1
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Pg.9-10; App. 4.1
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pg. 9-10; App. 4.1
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Pg. 9-10
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/a
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pg. 10-14
	23b	Discuss any limitations of the evidence included in the review.	Pg. 14-15
	23c	Discuss any limitations of the review processes used.	Pg. 14-15
	23d	Discuss implications of the results for practice, policy, and future research.	Pg. 10-14
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	N/a
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	N/a
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/a
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Pg. 2, 15
Competing interests	26	Declare any competing interests of review authors.	N/a
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	N/a

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71  
 For more information, visit: <http://www.prisma-statement.org/>

## Appendix 2: Search Strategy

### PubMed

overdose PWID

overdose IDU

fatal\* PWID

fatal\* IDU

mortal\* PWID

mortal\* IDU

overdose inject\* AND drug

((overdose or fatal\* or mortal\*) AND (inject\* or PWID or IDU)) AND (drug\* or narcotic) AND (NOT rat or mouse or mice))

(((((overdose or fatal or mortal) AND (inject or PWID or IDU)) AND (drug or narcotic))) ) AND ("2010"[Date - Publication] : "3000"[Date - Publication])) NOT (rat)) NOT (mouse)) NOT (mice)) NOT (dog)) NOT (horse)

("people who inject drugs"[tw] OR PWID\*[tw] OR "IV Drug User\*" OR "Intravenous Drug User\*" OR (Inject\* drug use\*[tw]) OR IDU[tw] OR "Substance Abuse, Intravenous"[Mesh] OR "Needle Sharing"[Mesh] AND (Overdose\*[tw]) AND (Fatal\*[tw] OR Mortal\*[tw] OR Death[tw] OR Surviv\*[tw]) AND English[lang] AND ("2010"[Date - Publication] : "2023"[Date - Publication]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])

### Embase

overdose pwid' OR ('overdose'/exp OR overdose) AND pwid)

overdose AND idu

fatal\* AND PWID

fatal\* AND idu

mortal\* AND pwid

mortal\* IDU

overdose AND inject\* AND drug

((('drug overdose'/exp OR 'drug overdose' OR fatal\* OR mortal\*:af) AND inject\* OR pwid OR 'idu'/exp OR idu) AND drug\* OR narcotic NOT ('rat'/exp OR rat) NOT ('mouse'/exp OR mouse) NOT ('mice'/exp OR mice) NOT ('dog'/exp OR dog) NOT ('horse'/exp OR horse) NOT ('animal'/exp OR animal) AND [1-1-2010]/sd NOT [29-9-2023]/sd

"""people who inject drugs""":ti,ab,kw,de OR PWID\*":ti,ab,kw,de OR ""IV Drug User"":ti,ab,kw,de OR ""Intravenous Drug User"":ti,ab,kw,de OR (Inject\* drug use\*":ti,ab,kw,de) OR IDU:ti,ab,kw,de OR 'substance abuse'/exp OR 'needle sharing/exp) AND (Overdose\*":ti,ab,kw,de) AND (Fatal\*":ti,ab,kw,de OR Mortal\*":ti,ab,kw,de OR Death:ti,ab,kw,de OR Surviv\*":ti,ab,kw,de) AND [english]/lim AND [2010-2023]/py NOT [animals]/lim"

### PsycINFO

overdose PWID

overdose IDU

fatal\* PWID

fatal\* IDU

mortal\* PWID

mortal\* IDU

overdose inject\* AND drug

(overdose or poisoning or toxicity) AND (fatal or injury) AND (mortality or mortality rate or death or death rate) AND inject\* OR (pwid or idu or injection drug users or injection drug addicts or people who inject drugs) AND drug use OR narcotics NOT (case report or case study or clinical case) NOT rats NOT (mouse or mice)

(TX ( "people who inject drugs" OR PWID\* OR "IV Drug User\*" OR "Intravenous Drug User\*" OR IDU ) OR TX (Inject\* drug use\*) OR (DE "Intravenous Drug Usage" OR DE "Needle Sharing")) AND TX (Overdose\*) AND TX (Fatal\* OR Mortal\* OR Death OR Surviv\*) AND (ZL "english") AND (DT 20100101-20230929) NOT (ZP "animal")

### ProQuest

(overdose pwid) AND (la.exact("ENG") AND pd(20100101-20230929))

(overdose idu) AND (la.exact("ENG") AND pd(20100101-20230929))

(fatal pwid) AND (la.exact("ENG") AND pd(20100101-20230929))

(fatal idu) AND (la.exact("ENG") AND pd(20100101-20230929))

(mortal pwid) AND (la.exact("ENG") AND pd(20100101-20230929))

(mortal idu) AND (la.exact("ENG") AND pd(20100101-20230929))

(Overdose inject AND drug) AND (la.exact("ENG") AND pd(20100101-20230929))

((overdose OR poisoning OR toxicity) AND (fatal OR injury) AND (mortality OR mortality rate OR death OR death rate) AND inject\* OR (pwid OR idu OR injection drug users OR injection drug addicts OR people who inject drugs) AND drug use OR narcotics NOT (case report OR case study OR clinical case) NOT rats NOT (mouse OR mice OR animal OR rat OR dog OR fish))

not(("people who inject drugs" OR PWID\* OR "IV Drug User\*" OR "Intravenous Drug User\*" OR (Inject\* drug use\*) OR IDU) AND (Overdose\*)) AND (Fatal\* OR Mortal\* OR Death OR Surviv\*))

Publication Year Limit: January 1, 2010 to September 29, 2023 (last searched September 29, 2023)

### Appendix 3: Risk of Bias Assessment Scores for Studies Included in the Meta-Analysis (N=58)

Reference	Location	Recruitment Site	Sample Size	PY Estimated	Definition
College-Frisbey et al. 2023	Australia	×	+	×	×
Conway et al., 2021	Australia	×	+	×	×
Geddes et al., 2021	Australia	×	+	×	×
Hill et al., 2022b	Australia	×	+	grey	grey
Kimber et al., 2019	Australia	×	+	grey	grey
Price et al., 2023	Australia	×	+	×	+
VanDenBoom et al., 2021	Australia	×	+	×	×
Bowles et al., 2021 <sup>¶</sup>	Canada	×	+	×	+
Hadland et al., 2014	Canada	×	+	+	+
Kennedy et al., 2019a	Canada	×	+	grey	grey
Kenny et al., 2022	Canada	×	+	×	+
Martel-Laferriere et al., 2022	Canada	×	×	grey	grey
McCrae et al., 2020	Canada	×	+	×	+
Roy et al., 2016	Canada	×	×	×	×
Rudzinski et al., 2021	Canada	×	×	×	×
Scheim et al., 2021	Canada	×	+	×	-
Selfridge et al., 2021	Canada	×	+	grey	grey
Shaw et al., 2015	Canada	+	+	×	×
Tarasuk et al., 2020	Canada	×	+	×	×
Vallance et al., 2018	Canada	×	+	×	×
Wallace et al., 2019	Canada	×	×	×	+
Bowles et al., 2021 <sup>¶</sup>	Mexico	×	+	×	+
West et al., 2020	Mexico	×	+	grey	grey
Bailey et al., 2022	NA	×	+	×	+
Byrne et al., 2022	UK	×	+	grey	grey
McAuley et al., 2023	UK	×	+	×	-
McDonald et al., 2021	UK	×	+	grey	grey
Spring et al., 2022	UK	×	+	×	-
Abadie et al., 2022	US	×	×	+	×
Ahmad et al., 2021	US	×	+	×	-
Armenta et al., 2015	US	×	+	+	+
Bluthenthal et al., 2020	US	×	+	×	×
Buresh et al., 2017	US	+	+	+	+
Calvo et al., 2017	US	×	×	×	-
Carlson et al., 2020	US	+	+	×	×
Chandra et al., 2021	US	×	×	×	×
Davis et al., 2017	US	+	+	grey	grey
Glick et al., 2021	US	×	+	×	+

Reference	Location	Recruitment Site	Sample Size	PY Estimated	Definition
Hayes et al., 2022	US	✗	+	✗	✗
Heimer et al., 2015	US	✗	+	✗	✗
Huang et al., 2018	US	✗	✗	●	●
Hunter et al., 2018	US	✗	+	✗	✗
Jones et al., 2022	US	+	+	✗	✗
Kinnard et al., 2021	US	✗	+	✗	✗
Lambdin et al., 2022	US	✗	✗	●	●
Lin et al., 2023	US	✗	+	✗	✗
Marcus et al., 2022	US	+	+	✗	+
McKnight et al., 2023	US	✗	+	✗	—
McMahan et al., 2020	US	✗	+	✗	+
Park et al., 2018	US	✗	+	✗	✗
Perez-Figueroa et al., 2022	US	✗	✗	✗	+
Pizzicato et al., 2020	US	✗	+	✗	+
Riley et al., 2016	US	✗	✗	+	+
Rosenthal. et al., 2020	US	✗	✗	●	●
Shrestha et al., 2021	US	✗	+	✗	✗
Stephens et al., 2014	US	✗	+	✗	✗
Tesfaye-Rogoza et al., 2020	US	✗	+	✗	✗
Tomko et al., 2022	US	+	+	✗	✗
Zhao et al., 2020	US	+	+	✗	—

#### Legend

- ⊕ Low Risk of Bias
- ⊖ Unclear Risk of Bias
- ✗ High Risk of Bias
- Not Applicable

#### Footnotes:

Abbreviations: Person-Years (PY); North America (NA); United Kingdom (UK); United States (US)

Studies only presenting fatal overdose measures were excluded from the PY and definition risk of bias assessments.

\* Participant recruitment conducted exclusively in the population (e.g., street recruitment) had low risk of bias. Studies that included participants recruited from venues (e.g., clinics, harm reduction programs) had high risk of bias.

§ Study sample sizes with ≥200 participants had low risk of bias and studies with sample sizes ≤199 participants had high risk of bias.

¶ Studies that reported PY directly had low risks of biases. Studies that did not report PY (i.e., PY had to be approximated) had high risks of biases.

† Definitions with low risk of bias were fully defined (e.g., [1] provides clear and concise references with [2] one or more limiting characteristics and [3] has an accompanying example) and overdose events without definitions had a high risk of bias. Studies that had partially defined (e.g., missing one or more definition components) overdose events that had uncertain risks of biases.

□ Bowles et al., 2021; This reference contains data collected from multiple countries. Reference appears twice in this table, referring to Canada and Mexico respectively.

## Appendix 4. Results Tables

### Appendix 4.1: Non-Fatal Overdose Sensitivity Analyses (2010 – 2023)

<b>Location</b>	<b>N</b>	<b>Rate (95% CI)<sup>§, □, *</sup></b>	<b>I<sup>2</sup> (%)</b>
<b>Overall</b>	46	30.46 (25.25 – 36.74) <sup>□</sup>	98.00
Provided PY	6	17.78 (12.40 – 25.47)	–
Approximated PY	40	32.94 (27.02 – 40.16)*	–
3 Month Recall	2	56.14 (38.22 – 82.45)	–
6 Month Recall	18	40.95 (28.67 – 58.50)	–
12 Month Recall	20	25.88 (21.51 – 31.14)*	–
<b>United States</b>	28	32.88 (26.43 – 40.91) <sup>□</sup>	96.60
Population-Based	6	40.18 (23.96 – 67.38)	–
Venue-Based	7	27.09 (21.12 – 34.76)	–
Mixed	15	33.20 (23.63 – 46.64)	

**Footnotes:**

Abbreviations: Sample Size (N); Confidence-Interval (CI); Person-years (PY)

\* Between group differences p-value ≤ 0.05

□ Q-test for heterogeneity p-value ≤ 0.05

§ Per 100 PY

## Appendix 4.2: Non-Fatal and Fatal Overdose Rates Estimates Among PWID (N=58)

Reference	Location	Data Collection		Study Design	N	PY	Non-Fatal Rate (95% CI) <sup>§</sup>	Fatal Rate (95% CI) <sup>‡,*§</sup>
		Years						
College-Frisbey et al., 2023	Australia	2017-2021		Cross-Sectional	965	965†	52.02 (47.66 — 56.78)	
Conway et al., 2021	Australia	2018-2019		Cross-Sectional	776	776†	10.18 (8.17—12.69)	
Geddes et al., 2021	Australia	2019		Cross-Sectional	2609	2609†	16.79 (15.29—18.44)	
Hill et al., 2022b	Australia	2008-2019		Longitudinal	1209	6913		0.51 (0.36—0.71)
Kimber et al., 2019	Australia	1999-2010		Longitudinal	215	2083		0.24 (0.10—0.58)
Price et al., 2023	Australia	2012-2022		Cross-Sectional	5657	5657†	17.96 (16.89—19.10)	
VanDenBoom et al., 2021	Australia	2018-2019		Cross-Sectional	658	658†	9.42 (7.35—12.09)	
Bowles et al., 2021 <sup>¶</sup>	Canada	2014-2018		Cross-Sectional	1328	664†	22.59 (19.25—26.51)	
Hadland et al., 2014	Canada	2005-2012		Longitudinal	414	763	9.04 (7.14—11.45)	
Kennedy et al., 2019a	Canada	2006-2017		Longitudinal	811	4872		0.39 (0.25—0.61)
Kenny et al., 2022	Canada	2019		Cross-Sectional	243	122†	97.54 (81.50—116.74)	
Martel-Laferriere et al., 2022	Canada	2017-2020		Longitudinal	62	24		4.17 (0.59—29.58)
McCrae et al., 2020	Canada	2018		Cross-Sectional	793	397†	32.24 (27.11—38.34)	
Roy et al., 2016	Canada	2012-2015		Longitudinal	122	31†	48.39 (29.17—80.26)	
Rudzinski et al., 2021	Canada	2018-2019		Cross-Sectional	15	8†	37.50 (12.09—116.27)	
Scheim et al., 2021	Canada	2018-2020		Cross-Sectional	699	350†	77.14 (68.47—86.92)	
Selfridge et al., 2021	Canada	2014-2019		Longitudinal	232	377		4.24 (2.60—6.93)
Shaw et al., 2015	Canada	2013		Cross-Sectional	272	272†	29.04 (23.30—36.21)	
Tarasuk et al., 2020	Canada	2017-2019		Cross-Sectional	1652	826†	45.28 (40.91—50.11)	
Vallance et al., 2018	Canada	2008-2015		Cross-Sectional	548	548†	18.61 (15.33—22.60)	
Wallace et al., 2019	Canada	2016		Cross-Sectional	187	94†	59.57 (45.85—77.41)	
Bowles et al., 2021 <sup>¶</sup>	Mexico	2014-2018		Cross-Sectional	666	333†	9.01 (6.30—12.89)	
West et al., 2020	Mexico	2011-2018		Longitudinal	658	3044		0.46 (0.27—0.78)
Bailey et al., 2022	Mexico & the US	2020-2021		Cross-Sectional	612	306†	31.70 (25.98—38.68)	
Byrne et al., 2022	UK	2017-2020		Longitudinal	231	1553		1.87 (1.30—2.69)
McAuley et al., 2023	UK	2019-2020		Cross-Sectional	1632	1632†	20.89 (18.79—23.23)	
McDonald et al., 2021	UK	2009-2018		Longitudinal	35065	236914		0.80 (0.77—0.84)
Spring et al., 2022	UK	2019		Cross-Sectional	2139	2139†	19.21 (17.44—21.16)	
Abadie et al., 2022	US	2015-2019		Longitudinal	66	132	17.42 (11.58—26.22)	
Ahmad et al., 2021	US	2018		Cross-Sectional	420	210†	85.24 (73.62—98.69)	
Armenta et al., 2015	US	2012-2015		Longitudinal	574	676	15.09 (12.43—18.32)	
Bluthenthal et al., 2020	US	2016-2017		Cross-Sectional	814	407†	55.53 (48.74—63.26)	
Buresh et al., 2017	US	2005-2013		Longitudinal	1310	2225	30.43 (28.22—32.81)	
Calvo et al., 2017	US	2014-2015		Cross-Sectional	107	107†	28.04 (19.60—40.10)	
Carlson et al., 2020	US	2017-2018		Cross-Sectional	225	113†	70.80 (56.86—88.14)	
Chandra et al., 2021	US	2018-2019		Cross-Sectional	104	104†	19.23 (12.41—29.81)	
Davis et al., 2017	US	1996-2011		Longitudinal	2007	5339		1.09 (0.84—1.41)
Glick et al., 2021	US	2017-2019		Cross-Sectional	720	720†	46.53 (41.80—51.79)	
Hayes et al., 2022	US	2018-2021		Cross-Sectional	1028	1028†	28.31 (25.23—31.75)	
Heimer et al., 2015	US	2008-2012		Cross-Sectional	456	456†	23.03 (19.02—27.88)	

## Appendix 4.2: Non-Fatal and Fatal Overdose Rates Estimates Among PWID (N=58)

Reference	Location	Data Collection		Study Design	N	PY	Non-Fatal Rate (95% CI) <sup>§</sup>	Fatal Rate (95% CI) <sup>‡,*§</sup>
		Years						
Huang et al., 2018	US	2004-2017		Longitudinal	76	76 <sup>†</sup>		1.32 (0.19—9.34)
Hunter et al., 2018	US	2016		Cross-Sectional	283	283 <sup>†</sup>	32.51 (26.50—39.88)	
Jones et al., 2022	US	2016-2019		Cross-Sectional	347	174 <sup>†</sup>	63.22 (52.44—76.21)	
Kinnard et al., 2021	US	2017-2018		Cross-Sectional	534	267 <sup>†</sup>	31.84 (25.74—39.38)	
Lambdin et al., 2022	US	2018-2020		Longitudinal	493	493 <sup>†</sup>		2.23 (1.24—4.03)
Lin et al., 2023	US	2018-2021		Cross-Sectional	258	129 <sup>†</sup>	72.09 (58.83—88.34)	
Marcus et al., 2022	US	2018		Cross-Sectional	10197	10197 <sup>†</sup>	28.22 (27.21—29.27)	
McKnight et al., 2023	US	2021-2022		Cross-Sectional	313	157 <sup>†</sup>	45.86 (36.40—57.78)	
McMahan et al., 2020	US	2019		Cross-Sectional	583	583 <sup>†</sup>	24.87 (21.14—29.27)	
Park et al., 2018	US	2016		Cross-Sectional	203	203 <sup>†</sup>	31.03 (24.24—39.73)	
Perez-Figueroa et al., 2022	US	2019		Cross-Sectional	62	16 <sup>†</sup>	68.75 (38.07—124.14)	
Pizzicato et al., 2020	US	2017-2018		Cross-Sectional	299	299 <sup>†</sup>	47.16 (39.98—55.62)	
Riley et al., 2016	US	2012-2014		Longitudinal	173	140	19.29 (13.23—28.12)	
Rosenthal. et al., 2020	US	2017-2018		Longitudinal	100	46	23.91 (13.24—43.18)	4.35 (1.09—17.38)
Shrestha et al., 2021	US	2017-2019		Cross-Sectional	279	279 <sup>†</sup>	47.31 (39.89—56.11)	
Stephens et al., 2014	US	2008-2010		Cross-Sectional	283	142 <sup>†</sup>	5.63 (2.82—11.27)	
Tesfaye-Rogoza et al., 2020	US	2017		Cross-Sectional	332	332 <sup>†</sup>	18.67 (14.56—23.95)	
Tomko et al., 2022	US	2018-2019		Cross-Sectional	238	119 <sup>†</sup>	74.79 (60.76—92.06)	
Zhao et al., 2020	US	2011-2013		Cross-Sectional	777	389 <sup>†</sup>	14.65 (11.30—19.00)	

### Footnotes:

Abbreviations: Sample Size (N); Person-Years (PY); Confidence Interval (CI)

<sup>†</sup> PY computed using the survey instrument's recall period.

<sup>‡</sup> Fatal overdose measured over follow-up period.

<sup>\*</sup> Excluding unconfirmed deaths.

<sup>§</sup> Rates per 100 PY

<sup>¶</sup> Bowles et al., 2021; This reference contains data collected from multiple countries. Reference appears twice in this table, referring to Canada and Mexico respectively.

### Appendix 4.3: Non-Analyzed Studies with Overlapping Data Summary Table (N=85)

Reference	Location	Source of Overlapping Data Included in Analyses	Data Collection Years	N	PY	Non-Fatal Events	Fatal Events
Cunningham et al., 2018	Australia	Martel-Laferriere et al., 2022; Selfridge et al., 2021	2016	103	71		1
Geddes et al., 2018	Australia	Geddes et al., 2021	2014	838	838 <sup>†</sup>	211	
Grebely et al., 2017	Australia	Martel-Laferriere et al., 2022; Selfridge et al., 2021	2016	103	48		1
Grebely et al., 2018	Australia	Martel-Laferriere et al., 2022; Selfridge et al., 2021	2016	102	6 <sup>†</sup>		1
Horyniak et al., 2013a	Australia	Price et al., 2023	2010-2011	991	496 <sup>†</sup>	53	
Horyniak et al., 2013b	Australia	Colledge-Frisby et al., 2023	2008-2010	688	344 <sup>†</sup>	68	
Iversen et al., 2017	Australia	Geddes et al., 2021	2014	1488	1488 <sup>†</sup>	309	
Nambiar et al., 2015	Australia	Hill et al., 2022b; Colledge-Frisby et al., 2023	2008-2012	665	333; 2277 <sup>†</sup>	10	12
Palmer et al., 2021	Australia	Colledge-Frisby et al., 2023	2017-2019	720	720 <sup>†</sup>	59	
Reddel et al., 2014	Australia	Price et al., 2023	2011	200	200 <sup>†</sup>	13	
Sutherland et al., 2021	Australia	Price et al., 2023	2011-2018	1766	1766 <sup>†</sup>	297	
Caudarella et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup> ; Kennedy et al., 2019a	1996-2011	2317	14996; 1499	1795	134
Cheng et al., 2016	Canada	Hadland et al., 2014	2008-2012	253	466	31	
Escudero et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup>	2006-2013	1760	7535	649	
Fairbairn et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2012	1114	4416	79	
Gaddis et al., 2017	Canada	Bowles et al., 2021 <sup>¶</sup>	2010-2012	1316	658 <sup>†</sup>	49	
Gower et al., 2022	Canada	Scheim et al., 2021	2016	200	100 <sup>†</sup>	16	
Hayashi et al., 2014	Canada	Kennedy et al., 2019a	1996-2011	2279	13597		110
Hayashi et al., 2016	Canada	Kennedy et al., 2019a	1996-2011	2317	14905		120
Hayashi et al., 2018	Canada	Bowles et al., 2021 <sup>¶</sup>	2016	669	335 <sup>†</sup>	85	
Hayashi et al., 2021	Canada	Bowles et al., 2021 <sup>¶</sup>	2016-2017	590	295 <sup>†</sup>	127	
Hyshka et al., 2015	Canada			279	140 <sup>†</sup>	62	
Ickowicz et al., 2017	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2014	626	313 <sup>†</sup>	40	
Ickowicz et al., 2020	Canada	Bowles et al., 2021 <sup>¶</sup>	2003-2017	793	397 <sup>†</sup>	86	
Ickowicz et al., 2022	Canada	Bowles et al., 2021 <sup>¶</sup>	2017-2018	730	365 <sup>†</sup>	167	
Kennedy et al., 2019b	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2016	1336	6254	136	
Kennedy et al., 2020	Canada	Bowles et al., 2021 <sup>¶</sup>	2017-2018	318	159 <sup>†</sup>	88	
Kennedy et al., 2022	Canada	Bowles et al., 2021 <sup>¶</sup>	2015-2018	745	373 <sup>†</sup>	79	
Lake et al., 2015a	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2014	1660	5343	670	
Lake et al., 2015b	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2013	1697	4736	570	
Lake et al., 2015c	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2013	1614	4724	558	
Mitra et al., 2022	Canada	Schiem et al., 2021	2018-2020	701	351 <sup>†</sup>	270	
Norton et al., 2022	Canada	Bowles et al., 2021 <sup>¶</sup>	2016-2018	1070	535 <sup>†</sup>	205	

### Appendix 4.3: Non-Analyzed Studies with Overlapping Data Summary Table (N=85)

Reference	Location	Source of Overlapping Data Included in Analyses	Data Collection Years	N	PY	Non-Fatal Events	Fatal Events
Pedersen et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2014	1119	560 <sup>†</sup>	91	
Prangnell et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2013	1142	571 <sup>†</sup>	72	
Prangnell et al., 2019	Canada	Bowles et al., 2021 <sup>¶</sup>	2012-2016	327	164 <sup>†</sup>	47	
Rammohan et al., 2022	Canada	Schiem et al., 2021	2018-2019	604	302 <sup>†</sup>	224	
Selfridge et al., 2019	Canada	Selfridge et al., 2021	2014-2017	132	171		9
Tarasuk et al., 2021	Canada	Tarasuk et al., 2020	2017-2019	997	499 <sup>†</sup>	185	
Tucker et al., 2015	Canada	Bowles et al., 2021 <sup>¶</sup>	2005-2013	1911	956 <sup>†</sup>	133	
Tucker et al., 2016	Canada	Bowles et al., 2021 <sup>¶</sup>	1996-2013	2806	1403 <sup>†</sup>	377	
Collins et al., 2016 <sup>○</sup>	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011-2014	735	368 <sup>†</sup>	74	
Horyniak et al., 2018	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011-2012	621	1921	59	
Meacham et al., 2015 <sup>§</sup>	Mexico	West et al., 2020	2011-2012	735	368 <sup>†</sup>	74	
Meacham et al., 2016	Mexico	Armenta et al., 2015	2011-2014	1311	656 <sup>†</sup>	119	
Meacham et al., 2018	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011-2012	735	368 <sup>†</sup>	74	
Rafful et al., 2015a	Mexico	Bowles et al., 2021 <sup>¶</sup>	2013	366	183 <sup>†</sup>	29	
Rafful et al., 2015b	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011	557	557	51	
Rafful et al., 2017	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011-2017	670	335 <sup>†</sup>	64	
Rivera Saldana et al., 2021	Mexico	Bowles et al., 2021 <sup>¶</sup>	2011-2013	661	1029	115	
West et al., 2018	Mexico	West et al., 2020	2011-2017	863	3132		35
Byrne et al., 2020	UK	Byrne et al., 2022	2018-2020	129	30		1
Dunleavy et al., 2021	UK	McAuley et al., 2023	2017-2018	1408	1408 <sup>†</sup>	260	
Hope et al., 2016	UK	Spring et al., 2022	2013	2047	2047 <sup>†</sup>	277	
O'Halloran et al., 2017	UK	Spring et al., 2022	2013-2014	3850	3850 <sup>†</sup>	591	
Trayner et al., 2020	UK	McAuley et al., 2023	2017-2018	1437	719 <sup>†</sup>	264	
Trayner et al., 2021	UK	McAuley et al., 2023	2017-2018	1421	1421 <sup>†</sup>	261	
Yuan et al., 2022	UK	Spring et al., 2022	2019	1972	1972 <sup>†</sup>	392	
Allen et al., 2019	US	Ahmad et al., 2021	2018	371	186 <sup>†</sup>	162	
Al-Tayyib et al., 2017a	US	Marcus et al., 2022	2015	599	599 <sup>†</sup>	128	
Al-Tayyib et al., 2017b	US	Marcus et al., 2022	2015	592	592 <sup>†</sup>	129	
Arreola et al., 2014	US	Zhao et al., 2020	2011-2013	696	348 <sup>†</sup>	46	
Cedarbaum et al., 2014	US	Glick et al., 2021	2013	389	389 <sup>†</sup>	94	
Cedarbaum et al., 2016	US	Glick et al., 2021	2013	389	389 <sup>†</sup>	95	
Chiang et al., 2022	US	Bluthenthal et al., 2020	2016-2018	601	301 <sup>†</sup>	85	
Collins et al., 2016 <sup>○</sup>	US	Armenta et al., 2015	2012-2014	291	146 <sup>†</sup>	23	
Frost et al., 2017	US	McMahn et al., 2020	2015	438	438 <sup>†</sup>	98	
Glick et al., 2018	US	Glick et al., 2021; Marcus et al., 2022	2009-2017	3844	3844 <sup>†</sup>	623	

### Appendix 4.3: Non-Analyzed Studies with Overlapping Data Summary Table (N=85)

Reference	Location	Source of Overlapping Data Included in Analyses	Data Collection Years	N	PY	Non-Fatal Events	Fatal Events
Heimer et al., 2014	US	Heimer et al., 2015	2008-2011	454	454 <sup>†</sup>	18	
Hill et al., 2022a	US	Rosenthal et al., 2020	2017	49	49 <sup>†</sup>	8	
Jarlais et al., 2023	US	McKnight et al., 2023	2021-2022	275	138 <sup>†</sup>	59	
Lipira et al., 2021	US	Marcus et al., 2022	2018-2019	610	610 <sup>†</sup>	156	
Mazhnaya et al., 2020	US	Ahmad et al., 2021	2018	311	156 <sup>†</sup>	161	
Meacham et al., 2015 <sup>§</sup>	US	Armenta et al., 2015	2012-2014	576	288 <sup>†</sup>	45	
Oh et al., 2020	US	Marcus et al., 2022	2018	458	458 <sup>†</sup>	233	
O'Rourke et al., 2019	US	Ahmad et al., 2021	2018	373	187 <sup>†</sup>	163	
Reid et al., 2023	US	Glick et al., 2021; Marcus et al., 2022	2018	550	550 <sup>†</sup>	143	
Rivera et al., 2022	US	Marcus et al., 2022	2018	503	503 <sup>†</sup>	125	
Robinson et al., 2017	US	Marcus et al., 2022	2012	1708	1708	232	
Rosenthal et al., 2019	US	Rosenthal et al., 2020		100	100	11	4
Rouhani et al., 2021	US	Ahmad et al., 2021	2018	420	210 <sup>†</sup>	179	
Rushmore et al., 2023	US	Marcus et al., 2022	2018	4420	4420 <sup>†</sup>	1344	
Simpson et al., 2021	US	Bluthenthal et al., 2021	2016-2018	531	266 <sup>†</sup>	84	
Tsui et al., 2018	US	Glick et al., 2021; Marcus et al., 2022	2015	486	486 <sup>†</sup>	106	
Wagner et al., 2014	US	Bowles et al., 2021 <sup>¶</sup>	2012-2013	480	240 <sup>†</sup>	39	
Wagner et al., 2015	US	Bowles et al., 2021 <sup>¶</sup>	2012-2014	573	287 <sup>†</sup>	45	
Nahass et al., 2021				30	30 <sup>†</sup>		1

#### Footnotes:

Abbreviations: Sample Size (N); Person-Years (PY)

All data reported here were excluded from the meta-analysis.


<sup>†</sup> PY computed using the survey instrument's recall period.

<sup>¤</sup> Collins et al., 2016; This reference contains data collected from multiple countries. This reference appears multiple times in this table as this meta-analysis analyzes data on country level differences.


<sup>§</sup> Meacham et al., 2015; This reference contains data collected from multiple countries. This reference appears multiple times in this table as this meta-analysis analyzes data on country level differences.

<sup>¶</sup> Bowles et al., 2021; This reference contains data collected from multiple countries. This reference appears multiple times in this table as this meta-analysis analyzes data on country level differences.


## Appendix 5. Overall Analyses Forest Plots




**Appendix 5.1: Random-Effects Meta-Analysis of North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY**



## Appendix 5.2: Random-Effects Meta-Analysis of North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY




**Appendix 5.3:** Random-Effects Meta-Analysis of North American Non-Fatal Overdose Rates Per 100 PY




#### Appendix 5.4: Random-Effects Meta-Analysis of North American Fatal Overdose Rates Per 100 PY


## Appendix 6. Post 2016 Analyses Forest Plots




### Appendix 6.1: Random-Effects Meta-Analysis of Post-2016 North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY




## Appendix 6.2: Random-Effects Meta-Analysis of Post-2016 North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY



### Appendix 6.3: Random-Effects Meta-Analysis of Post-2016 North American Non-Fatal Overdose Rates Per 100 PY




#### Appendix 6.4: Random-Effects Meta-Analysis of Post-2016 North American Fatal Overdose Rates Per 100 PY



Test for subgroup differences (random effects):  $\chi^2_4 = 58.19$ , df = 4 ( $p < 0.01$ )


## Appendix 6.5: Random-Effects Meta-Analysis of Post-2016 Country-Level Non-Fatal Overdose Rates Per 100 PY




Test for subgroup differences (random effects):  $\chi^2 = 3.01$ , df = 2 ( $p = 0.22$ )

## Appendix 6.6: Random-Effects Meta-Analysis of Post-2016 Country-Level Fatal Overdose Rates Per 100 PY

## Appendix 7. Line Plots



**Appendix 7.1: Line Plot of North American, United Kingdom, and Australian Non-Fatal Overdose Rates Per 100 PY**



**Appendix 7.2:** Line Plot of North American, United Kingdom, and Australian Fatal Overdose Rates Per 100 PY